

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : C07D 403/14, A61K 31/415	A1	(11) International Publication Number: WO 99/64413 (43) International Publication Date: 16 December 1999 (16.12.99)	
(21) International Application Number: PCT/EP99/03595 (22) International Filing Date: 22 May 1999 (22.05.99)	(81) Designated States: JP, US, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).		
(30) Priority Data: 9812211.2 5 June 1998 (05.06.98) GB	Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>		
(71) Applicant (for all designated States except US): PHARMACIA & UPJOHN S.P.A. [IT/IT]; Via Robert Koch, 1.2, I-20152 Milan (IT).			
(72) Inventors; and (75) Inventors/Applicants (for US only): COZZI, Paolo [IT/IT]; Via Zanella, 48/5, I-20133 Milan (IT). BARALDI, Pier, Giovanni [IT/IT]; Via Tulipani, 73, I-44100 Ferrara (IT). BERIA, Italo [IT/IT]; Via G. Matteotti, 39, I-45030 Villamarzana (IT). CALDARELLI, Marina [IT/IT]; Via Besenzzonica, 9, I-20147 Milan (IT). GERONI, Maria, Cristina [IT/IT]; Via Correggio, 48, I-20149 Milan (IT). PENNELLA, Giulia [IT/IT]; Via Pergine, 12, I-20148 Milan (IT). ROMAGNOLI, Romeo [IT/IT]; Via Bologna, 291, I-44100 Ferrara (IT).			
(54) Title: CINNAMOYL DISTAMYCIN ANALOGOUS DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS ANTITUMOR AGENTS			
<p style="text-align: center;">(I)</p>			
<p>(57) Abstract</p> <p>Compounds which are cinnamoyl distamycin derivatives of formula (I), wherein n is 2, 3 or 4; R₀ is C₁-C₄ alkyl or C₁-C₃ haloalkyl; R₁ and R₂, which are the same or different, are selected from hydrogen, C₁-C₄ alkyl optionally substituted by one or more fluorine atoms; and C₁-C₄ alkoxy; X is a halogen atom; Y and Z are the same or different and are selected, independently for each heterocyclic ring of the polyheterocyclic chain, from N and CH; B is selected from: (a), (b), (c), (d), (e), (f), (g) and (h), wherein R₃, R₄, R₅, R₆ and R₇ are, independently from each other, hydrogen or C₁-C₄ alkyl; or pharmaceutically acceptable salts thereof; provided that at least one of the heterocyclic rings within the polyheterocyclic chain is other than pyrrole; are useful as antitumor agents.</p>			

FOR THE PURPOSES OF INFORMATION ONLY


Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

**CINNAMOYL DISTAMYcin ANALOGOUS DERIVATIVES, PROCESS FOR
THEIR PREPARATION, AND THEIR USE AS ANTITUMOR AGENTS**

The present invention relates to new alkylating antitumor agents analogous to Distamycin A, to a process for their preparation, to pharmaceutical compositions containing them and to their use as therapeutic agents.

Distamycin A, whose formula is reported below



belongs to the family of the pyrroleamidine antibiotics and it is reported to interact reversibly and selectively with DNA-AT sequences, thus interfering with both replication and transcription. See, for a reference, *Nature*, 203, 1064 (1964); *FEBS Letters*, 7 (1970) 90; *Prog. Nucleic Acids Res. Mol. Biol.*, 15, 285 (1975).

Several analogous to distamycin are known in the art. DE-A-1795539 discloses distamycin derivatives in which the formyl group is replaced by a hydrogen atom or by the carboxylic acid residue of a C₁-C₄ aliphatic or cyclopentylpropionic acid.

EP-A-246,868 describes distamycin analogues in which the distamycin formyl group is substituted by aromatic, alicyclic or heterocyclic moieties bearing alkylating groups.

WO 97/28123 describes distamycin analogues in which the distamycin formyl group is substituted by an aromatic moiety bearing alkylating groups and the amidino group is replaced with different nitrogen-containing ending moieties.


WO 97/43258 discloses cinnamoyl distamycin derivatives amidino-modified as above reported.

Distamycin derivatives wherein at least one pyrrole ring of the polypyrrrole framework is substituted by an imidazole or

pyrazole ring are also reported in the literature; see, for a reference, Anti-Cancer Drug Design 8, 173-192 (1993); J. Am. Chem. Soc. Vol. 114, 5911-5919 (1992); Anti-Cancer Drug Design 6, 501-517 (1991); patent applications EP-A-0246868 and WO 96/05196.

It has now been found that a new class of distamycin derivatives as defined hereinunder, wherein at least one ring of the polypyrrole framework is other than pyrrole, the formyl group is substituted by a cinnamoyl moiety and the amidino group is optionally substituted by different nitrogen-containing ending groups, shows valuable biological properties.

Therefore, the present invention provides compounds which are cinnamoyl distamycin derivatives of formula:



wherein:

n is 2, 3 or 4;

R₀ is C₁-C₄ alkyl or C₁-C₄ haloalkyl;


R₁ and R₂, which are the same or different, are selected from hydrogen, C₁-C₄ alkyl optionally substituted by one or more fluorine atoms; and C₁-C₄ alkoxy;

X is a halogen atom;

Y and Z are the same or different and are selected, independently for each heterocyclic ring of the polyheterocyclic chain, from N and CH;

B is selected from:

-3-



wherein R₁, R₄, R₅, R₆, and R₇ are, independently from each other, hydrogen or C₁-C₄ alkyl;
 or pharmaceutically acceptable salts thereof;

5 provided that at least one of the heterocyclic rings within the polyheterocyclic chain is other than pyrrole.

The present invention includes within its scope also all the possible isomers covered by the compounds of formula
 10 (I), both separately and in admixture, as well as the metabolites and the pharmaceutically acceptable bio-precursors (otherwise known as pro-drugs) of the compounds of formula (I).

In the present description, unless otherwise specified,
 15 both terms alkyl and alkoxy include straight or branched C₁-C₄ alkyl and alkoxy groups such as, for instance, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec-butoxy and tert-butoxy.

20 Preferred C₁-C₄ alkyl or alkoxy groups are methyl, ethyl, methoxy and ethoxy groups.

When substituted by one or more fluorine atoms, the C₁-C₄ alkyl groups are preferably C₁-C₄ perfluoroalkyl groups, e.g. trifluoromethyl.

25 The term halogen atom includes fluorine, chlorine, bromine and iodine, being chlorine and bromine preferred.

As above reported, Y and Z are selected, independently for each heterocyclic ring of the polyheterocyclic chain, between N and CH. This means that within the compounds of
 30 formula (I) and for different heterocyclic rings Y can be either N as well as CH; the same applies for Z provided

that at least for one of the heterocyclic rings, Y and Z are not both CH.

Examples of the said heterocycles are pyrrole, pyrazole and imidazole.

5 Within the cinnamoyl derivatives of formula (I) the N,N-disubstituted amino group onto phenyl ring is in ortho, meta or para position; preferably, it is in meta or para position.

10 As to the R₁ and R₂ groups, they can be in any of the free positions of the phenyl ring.

Pharmaceutically acceptable salts of the compounds of formula (I) are their salts with pharmaceutically acceptable either inorganic or organic acids such as, for instance, hydrochloric, hydrobromic, sulfuric, nitric, 15 acetic, propionic, succinic, malonic, citric, tartaric, methanesulfonic and p-toluenesulfonic acid.

A preferred class of compounds of the present invention is that wherein, in formula (I):

20 n is 3;


R₀ is ethyl or 2-chloroethyl;

R₁ and R₂, which are the same or different, are selected from hydrogen, methyl, methoxy or trifluoromethyl;

X is chloro;

25 Y and Z are the same or different and are selected, independently for each heterocyclic ring of the polyheterocyclic chain, from N and CH;

B is selected from:



30

wherein R₃, R₄, R₅, R₆, and R₇ are, independently from each other, hydrogen or methyl;

or the pharmaceutically acceptable salts thereof;

provided that at least one of the heterocyclic rings within

35 the polyheterocyclic chain is other than pyrrole.

Examples of specific compounds according to the present invention, especially in the form of salts, preferably with hydrochloric acid, are the following:

3-[1-methyl-3[1-methyl-3[1-methyl-4[4-N,N-bis(2-chloroethyl)aminocinnamoylamido]pyrrole-2-carboxamido]pyrazole-5-carboxamido]pyrazole-5-carboxamido]propionamidine;

5 3-[1-methyl-3[1-methyl-3[1-methyl-4[4-N-ethyl-N-(2-chloroethyl)aminocinnamoylamido]pyrrole-2-carboxamido]pyrazole-5-carboxamido]propionamidine;

10 3-[1-methyl-3[1-methyl-3[1-methyl-4[3-N,N-bis(2-chloroethyl)aminocinnamoylamido]pyrrole-2-carboxamido]pyrazole-5-carboxamido]pyrazole-5-carboxamido]propionamidine;

15 3-[1-methyl-3[1-methyl-3[1-methyl-4[3-methyl-4-N,N-bis(2-chloroethyl)aminocinnamoyl]pyrrole-2-carboxamido]pyrazole-5-carboxamido]pyrazole-5-carboxamido]propionamidine;

20 3-[1-methyl-3[1-methyl-4[1-methyl-4[4-N,N-bis(2-chloroethyl)aminocinnamoylamido]pyrrole-2-carboxamido]pyrazole-5-carboxamido]propionamidine;

25 3-[1-methyl-3[1-methyl-4[1-methyl-4[4-N-ethyl-N(2-chloroethyl)aminocinnamoylamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]pyrazole-5-carboxamido]propionamidine;

30 3-[1-methyl-4[1-methyl-4[1-methyl-4[4-N,N-bis(2-chloroethyl)aminocinnamoylamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]imidazole-2-carboxamido]propionamidine;

35 3-[1-methyl-4[1-methyl-3[1-methyl-4[4-N,N-bis(2-chloroethyl)aminocinnamoylamido]pyrrole-2-carboxamido]pyrazole-5-carboxamido]pyrrole-2-

carboxamido]propionamidine;
3-[1-methyl-3[1-methyl-3[1-methyl-4[4-N,N-bis(2-chloroethyl)aminocinnamoylamido]pyrrole-2-carboxamido]pyrazole-5-carboxamido]pyrazole-5-
5 carboxamido]propioncyanamidine;
3-[1-methyl-3[1-methyl-4[1-methyl-4[4-N,N-bis(2-chloroethyl)aminocinnamoylamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]pyrazole-5-carboxamido]propioncyanamidine;
10 3-[1-methyl-4[1-methyl-4[1-methyl-4[4-N,N-bis(2-chloroethyl)aminocinnamoylamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]imidazole-2-
carboxamido]propioncyanamidine;
3-[1-methyl-4[1-methyl-3[1-methyl-4[4-N,N-bis(2-chloroethyl)aminocinnamoylamido]pyrrole-2-
15 carboxamido]pyrazole-5-carboxamido]imidazole-2-
carboxamido]propioncyanamidine;
3-[1-methyl-4[1-methyl-3[1-methyl-4[4-N,N-bis(2-chloroethyl)aminocinnamoylamido]pyrrole-2-
carboxamido]pyrazole-5-carboxamido]pyrrole-2-
20 carboxamido]propioncyanamidine;
3-[1-methyl-4[1-methyl-4[1-methyl-4[4-N-ethyl-N(2-chloroethyl)aminocinnamoylamido]pyrrole-2-
carboxamido]pyrrole-2-carboxamido]imidazole-2-
25 carboxamido]propioncyanamidine;
3-[1-methyl-4[1-methyl-3[1-methyl-4[4-N-ethylN(2-chloroethyl)aminocinnamoylamido]pyrrole-2-
carboxamido]pyrazole-5-carboxamido]imidazole-2-
carboxamido]propioncyanamidine;
30 3-[1-methyl-3[1-methyl-3[1-methyl-4[4-N,N-bis(2-chloroethyl)aminocinnamoylamido]pyrrole-2-
carboxamido]pyrazole-5-carboxamido]pyrazole-5-
carboxamido]propionamidoxime;
3-[1-methyl-3[1-methyl-4[1-methyl-4[4-N,N-bis(2-chloroethyl)aminocinnamoylamido]pyrrole-2-
35 carboxamido]pyrrole-2-carboxamido]pyrazole-5-
carboxamido]propionamidoxime;

3-[1-methyl-4[1-methyl-4[1-methyl-4[N,N-bis(2-chloroethyl)aminocinnamoylamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]imidazole-2-carboxamido]propionamidoxime;

5 3-[1-methyl-4[1-methyl-3[1-methyl-4[N,N-bis(2-chloroethyl)aminocinnamoylamido]pyrrole-2-carboxamido]pyrazole-5-carboxamido]imidazole-2-carboxamido]propionamidoxime;

10 3-[1-methyl-4[1-methyl-3[1-methyl-4[N,N-bis(2-chloroethyl)aminocinnamoylamido]pyrrole-2-carboxamido]pyrazole-5-carboxamido]pyrrole-2-carboxamido]propionamidoxime;

15 3-[1-methyl-3[1-methyl-3[1-methyl-4[4-N-ethyl-N(2-chloroethyl)aminocinnamoylamido]pyrrole-2-carboxamido]pyrazole-5-carboxamido]pyrazole-5-carboxamido]propionamidoxime;

20 3-[1-methyl-3[1-methyl-4[1-methyl-4[3-methyl-4[N,N-bis(2-chloroethyl)aminocinnamoylamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]pyrazole-5-carboxamido]propionamidoxime;

25 3-[1-methyl-3[1-methyl-3[1-methyl-4[4-N,N-bis(2-chloroethyl)aminocinnamoylamido]pyrrole-2-carboxamido]pyrazole-5-carboxamido]pyrazole-5-carboxamido]propionitrile;

30 3-[1-methyl-4[1-methyl-4[1-methyl-4[N,N-bis(2-chloroethyl)aminocinnamoylamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]imidazole-2-carboxamido]propionitrile;

35 3-[1-methyl-4[1-methyl-3[1-methyl-4[N,N-bis(2-chloroethyl)aminocinnamoylamido]pyrrole-2-carboxamido]pyrazole-5-carboxamido]imidazole-2-carboxamido]propionitrile;

3-[1-methyl-4[1-methyl-3[1-methyl-4[N,N-bis(2-


chloroethyl)aminocinnamoylamido]pyrrole-2-
carboxamido]pyrazole-5-carboxamido]pyrrole-2-
carboxamido]propionitrile;
3-[1-methyl-3[1-methyl-3[1-methyl-4[4-N,N-bis(2-
5 chloroethyl)aminocinnamoylamido]pyrrole-2-
carboxamido]pyrazole-5-carboxamido]pyrazole-5-
carboxamido]propionamide;
3-[1-methyl-3[1-methyl-4[1-methyl-4[4-N-ethyl-N(2-
chloroethyl)aminocinnamoylamido]pyrrole-2-
10 carboxamido]pyrrole-2-carboxamido]pyrazole-5-
carboxamido]propionamide;
3-[1-methyl-4[1-methyl-4[1-methyl-4[4-N,N-bis(2-
chloroethyl)aminocinnamoylamido]pyrrole-2-
carboxamido]pyrrole-2-carboxamido]imidazole-2-
15 carboxamido]propionamide;
3-[1-methyl-4[1-methyl-3[1-methyl-4[4-N,N-bis(2-
chloroethyl)aminocinnamoylamido]pyrrole-2-
carboxamido]pyrazole-5-carboxamido]imidazole-2-
carboxamido]propionamide;
20 3-[1-methyl-3[1-methyl-3[1-methyl-4[4-N,N-bis(2-
chloroethyl)aminocinnamoylamido]pyrrole-2-
carboxamido]pyrazole-5-carboxamido]pyrazole-5-
carboxamido]propion-N-methyl-amidine;
3-[1-methyl-3[1-methyl-4[1-methyl-4[4-N,N-bis(2-
25 chloroethyl)aminocinnamoylamido]pyrrole-2-
carboxamido]pyrrole-2-carboxamido]pyrazole-5-
carboxamido]propion-N-methyl-amidine;
3-[1-methyl-4[1-methyl-4[1-methyl-4[4-N,N-bis(2-
chloroethyl)aminocinnamoylamido]pyrrole-2-
30 carboxamido]pyrrole-2-carboxamido]imidazole-2-
carboxamido]propion-N-methyl-amidine;
3-[1-methyl-4[1-methyl-3[1-methyl-4[4-N,N-bis(2-
chloroethyl)aminocinnamoylamido]pyrrole-2-
carboxamido]pyrazole-5-carboxamido]imidazole-2-
35 carboxamido]propion-N-methyl-amidine;
3-[1-methyl-3[1-methyl-3[1-methyl-4[4-N,N-bis(2-
chloroethyl)aminocinnamoylamido]pyrrole-2-

carboxamido]pyrazole-5-carboxamido]pyrazole-5-
carboxamido]propion-N,N'-dimethyl-amidine;
3-[1-methyl-3[1-methyl-4[1-methyl-4[4-N,N-bis(2-
chloroethyl)aminocinnamoylamido]pyrrole-2-
5 carboxamido]pyrrole-2-carboxamido]pyrazole-5-
carboxamido]propion-N,N'-dimethyl-amidine;
3-[1-methyl-4[1-methyl-4[1-methyl-4[4-N,N-bis(2-
chloroethyl)aminocinnamoylamido]pyrrole-2-
carboxamido]pyrrole-2-carboxamido]imidazole-2-
10 carboxamido]propion-N,N'-dimethyl-amidine;
3-[1-methyl-4[1-methyl-3[1-methyl-4[4-N,N-bis(2-
chloroethyl)aminocinnamoylamido]pyrrole-2-
carboxamido]pyrazole-5-carboxamido]imidazole-2-
carboxamido] propion-N,N'-dimethyl-amidine;
15 3-[1-methyl-4[1-methyl-3[1-methyl-4[4-N,N-bis(2-
chloroethyl)aminocinnamoylamido]pyrrole-2-
carboxamido]pyrazole-5-carboxamido]pyrrole-2-
carboxamido]propion-N,N'-dimethyl-amidine;
3-[1-methyl-3[1-methyl-3[1-methyl-4[3-methyl-4-N,N-bis(2-
20 chloroethyl)aminocinnamoylamido]pyrrole-2-
carboxamido]pyrazole-5-carboxamido]pyrazole-5-carboxamido]
propion-N,N'-dimethyl-amidine;
3-[1-methyl-4[1-methyl-4[1-methyl-4[4-N-ethyl-N(2-
chloroethyl)aminocinnamoylamido]pyrrole-2-
25 carboxamido]pyrrole-2-carboxamido]imidazole-2-
carboxamido]propion-N,N'-dimethyl-amidine;
2-[1-methyl-3[1-methyl-3[1-methyl-4[4-N,N-bis(2-
chloroethyl)aminocinnamoylamido]pyrrole-2-
carboxamido]pyrazole-5-carboxamido]pyrazole-5-
30 carboxamido]ethylguanidine;
2-[1-methyl-3[1-methyl-4[1-methyl-4[4-N,N-bis(2-
chloroethyl)aminocinnamoylamido]pyrrole-2-
carboxamido]pyrrole-2-carboxamido]pyrazole-5-
carboxamido]ethylguanidine;
35 2-[1-methyl-4[1-methyl-4[1-methyl-4[4-N,N-bis(2-
chloroethyl)aminocinnamoylamido]pyrrole-2-
carboxamido]pyrrole-2-carboxamido]imidazole-2-


carboxamido]ethylguanidine;
 2-[1-methyl-3[1-methyl-3[1-methyl-4[3-N,N-bis(2-chloroethyl)aminocinnamoylamido]pyrrole-2-carboxamido]pyrazole-5-carboxamido]pyrazole-5-carboxamido]ethylguanidine.

A further object of the present invention is a process for preparing the compounds of formula (I), and the pharmaceutically acceptable salts thereof, which process comprises:


10 (a) when B is other than guanidino;
 reacting a compound of formula:



with a compound of formula:




15 wherein n, X, R₀, R₁, R₂, Y and Z are as defined above;
 and E is hydroxy or a suitable leaving group;
 so as to obtain a compound of formula:




and then, optionally reacting a compound of formula
 20 (Ia) with:
 (i) H₂N-(CH₂)_r-NH₂, wherein r is 2 or 3, so as to obtain a compound of formula (I) having B equal to:


-11-




(ii) $\text{H}_2\text{N}-\text{CN}$, so obtaining a compound of formula (I) having B equal to:



5 (iii) $\text{H}_2\text{N}-\text{OH}$, so obtaining a compound of formula (I) having B equal to:




(iv) HNR_4R_5 , so obtaining a compound of formula (I) having B equal to:



10

and then optionally with H_2NR_3 , so obtaining a compound of formula (I) having B equal to:




(v) succinic anhydride, so obtaining a compound of formula (I) having B equal to $-\text{C}\equiv\text{N}$;

15 (vi) water in an alkaline medium, so obtaining a compound of formula (I) having B equal to $-\text{CONR}_6\text{R}$, wherein R_6 and R , are both hydrogen atoms;

(vii) HNR_6R_7 , so obtaining a compound of formula (I) having B equal to:


20




and then with water in an alkaline medium, so obtaining a compound of formula (I) having B equal to $-\text{CONR}_6\text{R}$,

wherein R₆ and R₇ are, each independently, hydrogen or C₁-C₄ alkyl; or:

(b) reacting a compound of formula:



5 with a compound of formula:



wherein n, B, Y, Z, X, R₀, R₁, R₂ and E are as defined above;

so obtaining the corresponding compound of formula (I);
10 and, if desired, converting the compound of formula (I) prepared according to processes (a) or (b) into a pharmaceutically acceptable salt thereof.

In formula (III), E is hydroxy or a leaving group selected,
15 for instance, from chloro, 2,4,5-trichlorophenoxy, 2,4-dinitro-phenoxy, succinimido-N-oxy, imidazolyl group, and the like.

The condensation reactions between a compound of formula (II) or of formula (IV) with a compound of formula (III),
20 as defined above according to processes a) or b), can be carried out by known methods, for instance those reported in the aforementioned EP-A-246868.

Likewise, the reaction between a compound of formula (Ia) and one of the reactants as defined under points (i-vii)
25 can be carried out according to known methods, for instance as described in WO 97/43258.

The compounds of formula (II) are known or may be prepared by known methods; see, for a reference, Arcamone et al. in Gazzetta Chim. Ital. 97, 1097 (1967).

Also the compounds of formula (III) and (IV) are known or may be prepared according to well-known reactions in organic chemistry, for instance as reported in WO 97/43258. Salification of a compound of formula (I), as well as preparation of a free compound starting from a salt, may be carried out by known standard methods.

Well known procedures such as, e.g., fractional crystallisation or chromatography, may also be followed for separating a mixture of isomers of formula (I) into the single isomers.

The compounds of formula (I) may be purified by conventional techniques such as, e.g., silica gel or alumina column chromatography, and/or by recrystallisation from an organic solvent such as, e.g., a lower aliphatic alcohol, e.g. methyl, ethyl or isopropyl alcohol, or dimethylformamide.

Pharmacology

The compounds of formula (I) according to the present invention are useful as antineoplastic agents.

Particularly, they show cytostatic properties towards tumor cells, so that they can be useful to inhibit growth of various tumors in mammals, including humans, such as, for instance, carcinomas, e.g. mammary carcinoma, lung carcinoma, bladder carcinoma, colon carcinoma, ovary and endometrial tumors. Other neoplasias in which the compounds of the present invention can find application are, for instance, sarcomas, e.g. soft tissue and bone sarcomas, and the hematological malignancies such as, e.g. leukemias.

The in vitro antitumor activity of the compounds of formula (I) was evaluated by cytotoxicity studies carried out on murine L1210 leukemia cells. Cells were derived from in vivo tumors and established in cell culture. The inhibition of cell growth was determined by counting surviving cells with a Coulter Counter after 48 hours treatment.

The in vitro activity was calculated on concentration-response curves and reported as IC₅₀ (concentration

inhibiting 50% of the cellular growth in respect to controls) were calculated on dose-response.

The compounds of the invention were tested also in vivo on L1210 murine leukemia and on murine reticulosarcoma M 5076,
5 showing a very good antitumoral activity, with the following procedure.

L1210 murine leukemia was maintained in vivo by i.p. weekly transplantation in CD2F1 female mice, obtained from Charles River Italy. For experiments, 10^5 cells/mouse were injected
10 i.v. in the same strain of mice. Animals were 8 to 10 weeks old at the beginning of the experiments. Compounds were administered i.v. at day +1 after tumor cells injections.

M5076 reticulosarcoma was maintained in vivo by i.m. serial transplantation. For experiments, 5×10^5 cells/mice were
15 injected i.m. in the same strain of mice. Animals were 8 to 10 weeks old at the beginning of the experiments. Compounds were administered i.v. at day 3, 7 and 11 after tumor injection.

Survival time of mice and tumor growth were calculated and
20 activity was expressed in term of T/C% and T.I.%.

$$T/C = \frac{\text{median survival time treated group}}{\text{median survival time untreated group}} \times 100$$

25

$$T.I. = \% \text{ inhibition of tumor growth respect to control}$$

Tox = number of mice which died for toxicity.

Tox determination was made when mice died before the control
30 and/or tested significant body weight loss and/or spleen and/or liver size reduction were observed.

The compounds of the invention can be administered to mammals, including humans, through the usual routes, for example, parenterally, e.g. by intravenous injection or
35 infusion, intramuscularly, subcutaneously, topically or orally. The dosage depends on age, weight and conditions of the patient and on the administration route. For example, a suitable dosage for administration to adult humans may

range from about 0.1 to about 150-200 mg pro dose 1-4 times a day.

Further object of the present invention are pharmaceutical compositions, which comprise a compound of formula (I) as 5 an active principle, in association with one or more pharmaceutically acceptable carrier and/or diluent.

The pharmaceutical compositions of the present invention are usually prepared following conventional methods and are administered in a pharmaceutically suitable form. For 10 instance, solutions for intravenous injection or infusion may contain as a carrier, for example, sterile water or preferably, they may be in the form of sterile aqueous isotonic saline solutions.

Suspensions or solutions for intramuscular injections may 15 contain, together with the active compound a pharmaceutically acceptable carrier, e.g. sterile water, olive oil, ethyl oleate, glycols, e.g. propylene glycol, and if desired, a suitable amount of lidocaine hydrochloride.

20 In the forms for topical application, e.g. creams, lotions or pastes for use in dermatological treatment, the active ingredient may be mixed with conventional oleaginous or emulsifying excipients.

The solid oral forms, e.g. tablets and capsules, may 25 contain, together with the active compound, diluents, e.g., lactose, dextrose, saccharose, cellulose, corn starch and potato starch; lubricants, e.g. silica, talc, stearic acid, magnesium or calcium stearate, and/or polyethylene glycols; binding agents, e.g. starches, arabic gums, gelatin, 30 methylcellulose, carboxymethyl cellulose, polyvinyl-pyrrolidone; disaggregating agents, e.g. starch, alginic acid, alginates, sodium starch glycolate; effervescent mixtures; dyestuffs; sweeteners; wetting agents, for instance, lecithin, polysorbates, laurylsulphates; and, in 35 general, non-toxic and pharmacologically inactive substances used in pharmaceutical formulation. Said pharmaceutical preparations may be manufactured by known

techniques, for example by means of mixing, granulating, tabletting, sugar-coating or film-coating processes.

Further object of the present invention are the compounds of formula (I) for use in a method for treating the human
5 or animal body by therapy.

Furthermore, the present invention provides a method for treating tumors in a patient in need of it, which comprises administering to said patient a composition of the invention.

10 A further object of the present invention is a combined method for treating cancer or for ameliorating the conditions of mammals, including humans, suffering from cancer, said method comprising administering a compound of formula (I), or a pharmaceutically acceptable salt thereof,
15 and an additional antitumor agent, close enough in time and in amounts sufficient to produce a therapeutically useful effect.

The present invention also provides products containing a compound of formula (I), or a pharmaceutically acceptable
20 salt thereof, and an additional antitumour agent as a combined preparation for simultaneous, separate or sequential use in anti-cancer therapy.

The term "antitumor agent" is meant to comprise both a single antitumor drug and "cocktails" i.e. a mixture of
25 such drugs, according to the clinical practice. Examples of antitumor agents that can be formulated with a compound of formula (I), or alternatively, can be administered in a combined method of treatment, include doxorubicin, daunomycin, epirubicin, idarubicin, etoposide, fluoro-
30 uracil, melphalan, cyclophosphamide, 4-demethoxy daunorubicin, bleomycin, vinblastin, and mitomycin, or mixtures thereof.

The following examples are given to better illustrate the present invention but do not limit the scope of the
35 invention itself.

Example 1

3-[1-methyl-3[1-methyl-3[1-methyl-4[4-N,N-bis(2-chloroethyl)aminocinnamoylamido]pyrrole-2-carboxamido]pyrazole-5-carboxamido]pyrazole-5-carboxamido]propionamidine

5 A solution of 4-N,N'-bis(2-chloroethyl)amino-1-cinnamic acid (200 mg) (prepared as reported in WO 97/43258), dicyclohexylcarbodiimide (162 mg), 1-hydroxybenzotriazole hydrate (106 mg) in DMF (10 ml) was stirred at 70°C for four hours, cooled to room temperature and then added of 3-[1-methyl-3-[1-methyl-3-[1-methyl-4-aminopyrrole-2-carboxamido]pyrazole-5-carboxamido]pyrazole-5-carboxamido]propionamidine dihydrochloride (310 mg) (prepared as reported in WO 96/05196) and potassium bicarbonate (118 mg).

10 The mixture was stirred at room temperature for 3 hours, the solvent was evaporated in vacuo and the crude residue purified by flash chromatography (methylene chloride/methanol: 8/2) to yield the title compound as an orange powder (180 mg).

15 FAB-MS: m/z 725, (100, [M+H]⁺)

PMR (DMSO-d₆) δ :

11.10 (s, 1H), 10.50 (s, 1H), 10.00 (s, 1H), 8.77 (t, J=5.7Hz, 1H), 8.79 (b.s., 2H), 8.58 (b.s., 2H), 7.52 (s, 1H), 7.42 (m, 2H), 7.39 (d, J=1.6 Hz, 1H), 7.38 (d, J=15.7Hz, 1H), 7.29 (s, 1H), 7.01 (d, J=1.6 Hz, 1H), 6.79 (m, 2H), 6.55 (d, J=15.7 Hz, 1H), 4.04 (s, 3H), 4.01 (s, 3H), 3.86 (s, 3H), 3.76 (m, 8H), 3.50 (m, 2H), 2.61 (t, J=6.3 Hz, 2H).

20 By analogous procedure and using the opportune starting materials the following products can be obtained:

3-[1-methyl-3[1-methyl-3[1-methyl-4[4-N-ethyl-N-(2-chloroethyl)aminocinnamoylamido]pyrrole-2-carboxamido]pyrazole-5-carboxamido]propionamidine;

25 3-[1-methyl-3[1-methyl-3[1-methyl-4[3-N,N-bis(2-chloroethyl)aminocinnamoylamido]pyrrole-2-carboxamido]pyrazole-5-carboxamido]pyrazole-5-

carboxamido]propionamidine;
3-[1-methyl-3[1-methyl-3[1-methyl-4[4-N,N-bis(2-chloroethyl)amino-3-methylcinnamoyl]pyrrole-2-carboxamido]pyrazole-5-carboxamido]pyrazole-5-carboxamido]
5 propionamidine;
3-[1-methyl-3[1-methyl-4[1-methyl-4[4-N,N-bis(2-chloroethyl)aminocinnamoylamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]pyrazole-5-carboxamido]propionamidine;
10 3-[1-methyl-3[1-methyl-4[1-methyl-4[4-N-ethyl-N(2-chloroethyl)aminocinnamoylamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]pyrazole-5-carboxamido]propionamidine;
3-[1-methyl-4[1-methyl-4[1-methyl-4[4-N,N-bis(2-chloroethyl)aminocinnamoylamido]pyrrole-2-
15 carboxamido]pyrrole-2-carboxamido]imidazole-2-carboxamido]propionamidine;
3-[1-methyl-4[1-methyl-3[1-methyl-4[4-N,N-bis(2-chloroethyl)aminocinnamoylamido]pyrrole-2-
20 carboxamido]pyrazole-5-carboxamido]imidazole-2-carboxamido]propionamidine;
3-[1-methyl-4[1-methyl-3[1-methyl-4[4-N,N-bis(2-chloroethyl)aminocinnamoylamido]pyrrole-2-
25 carboxamido]pyrazole-5-carboxamido]propionamidine;
3-[1-methyl-4[1-methyl-4[1-methyl-4[4-N,N-bis(2-chloroethyl)aminocinnamoylamido]pyrrole-2-
carboxamido]pyrrole-2-carboxamido]imidazole-2-carboxamido]propioncyanamidine;
30 3-[1-methyl-4[1-methyl-3[1-methyl-4[4-N,N-bis(2-chloroethyl)aminocinnamoylamido]pyrrole-2-
carboxamido]pyrazole-5-carboxamido]pyrrole-2-carboxamido]propioncyanamidine;
3-[1-methyl-4[1-methyl-3[1-methyl-4[4-N,N-bis(2-
35 chloroethyl)aminocinnamoylamido]pyrrole-2-
carboxamido]pyrazole-5-carboxamido]imidazole-2-
carboxamido]propionamidoxime;

3-[1-methyl-3[1-methyl-3[1-methyl-4[4-N-ethyl-N(2-chloroethyl)aminocinnamoylamido]pyrrole-2-carboxamido]pyrazole-5-carboxamido]pyrazole-5-carboxamido]propionamidoxime;

5 3-[1-methyl-3[1-methyl-4[1-methyl-4[4-N,N-bis(2-chloroethyl)aminocinnamoylamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]pyrazole-5-carboxamido]propionitrile;

10 3-[1-methyl-4[1-methyl-4[1-methyl-4[4-N,N-bis(2-chloroethyl)aminocinnamoylamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]imidazole-2-carboxamido]propionitrile;

15 3-[1-methyl-3[1-methyl-4[1-methyl-4[4-N-ethyl-N(2-chloroethyl)aminocinnamoylamido]pyrrole-2-carboxamido]pyrrole-5-carboxamido]pyrazole-5-carboxamido]propionamide;

20 3-[1-methyl-3[1-methyl-3[1-methyl-4[4-N,N-bis(2-chloroethyl)aminocinnamoylamido]pyrrole-2-carboxamido]pyrazole-5-carboxamido]pyrazole-5-carboxamido]propion-N-methyl-amidine;

25 3-[1-methyl-4[1-methyl-3[1-methyl-4[4-N,N-bis(2-chloroethyl)aminocinnamoylamido]pyrrole-2-carboxamido]pyrazole-5-carboxamido]imidazole-2-carboxamido]propion-N-methyl-amidine;

30 3-[1-methyl-4[1-methyl-3[1-methyl-4[4-N,N-bis(2-chloroethyl)aminocinnamoylamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]imidazole-2-carboxamido]propion-N,N'-dimethyl-amidine;

35 3-[1-methyl-4[1-methyl-4[1-methyl-4[4-N-ethyl-N(2-chloroethyl)aminocinnamoylamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]pyrazole-5-carboxamido]ethylguanidine.

Example 2

3-[1-methyl-3[1-methyl-3[1-methyl-4[4-N,N-bis(2-chloroethyl)aminocinnamoylamido]pyrrole-2-carboxamido]pyrazole-5-carboxamido]pyrazole-5-carboxamido]propion-N,N'-dimethylamidine

A solution of 3-[1-methyl-3[1-methyl-3[1-methyl-4[4-N,N-bis(2-chloroethyl)aminocinnamoylamido]pyrrole-2-carboxamido]pyrazole-5-carboxamido]propionamide (500 mg) (prepared as reported in example 1) in DMF (20 ml) was heated at 80°C and treated with methylamine hydrochloride 80% (2 ml). After 4 hours additonal methylamine hydrochloride 80% (2 ml) was added. The solution was evaporated to dryness and the crude residue purified by flash chromatography (methylene chloride/methanol : 8/2) yielding the title compound as a pale yellow powder (300 mg).

FAB-MS: m/z 753, (100, [M+H]⁺)

PMR (DMSO-d₆) δ :

11.14 (s, 1H), 10.52 (s, 1H), 10.02 (s, 1H), 9.48 (q, J=4.7Hz, 1H), 8.85 (t, J=5.7Hz, 1H), 8.73 (q, J=4.7 Hz, 1H), 7.53 (s, 1H), 7.43 (m, 2H), 7.40 (d, J=1.8 Hz, 1H), 7.38 (d, J=15.7Hz), 7.27 (s, 1H), 7.01 (d, J=1.8 Hz, 1H), 6.79 (m, 2H), 6.55 (d, J=15.7Hz), 4.03 (s, 3H), 4.00 (s, 3H), 3.86 (s, 3H), 3.75 (m, 8H), 3.50 (m, 2H), 3.00 (d, J=4.7 Hz, 3H), 2.77 (d, J=4.7Hz, 3H), 2.74 (t, J=6.6Hz, 2H).

By analogous procedure and using the opportune starting materials the following products can be obtained:

3-[1-methyl-3[1-methyl-3[1-methyl-4[4-N,N-bis(2-chloroethyl)aminocinnamoylamido]pyrrole-2-carboxamido]pyrazole-5-carboxamido]propionamide;

FAB-MS: m/z 726, (100, [M+H]⁺)

PMR (DMSO-d₆) δ :

11.08 (s, 1H), 10.50 (s, 1H), 9.99 (s, 1H), 8.59 (t, J=5.7Hz, 1H), 7.52 (s, 1H), 7.43 (m, 2H), 7.39 (d, J=1.9 Hz, 1H), 7.37 (d, J=15.6Hz), 7.33 (s, 1H), 7.24 (s, 1H),

7.00 (d, J=1.9 Hz, 1H), 6.82 (s, 1H), 6.79 (m, 2H), 6.54 (d, J=15.6Hz), 4.03 (s, 3H), 4.00 (s, 3H), 3.86 (s, 3H), 3.75 (m, 8H), 3.38 (m, 2H), 2.33 (t, J=7.1Hz, 2H);
3-[1-methyl-3[1-methyl-3[1-methyl-4[4-N,N-bis(2-
5 chloroethyl)aminocinnamoylamido]pyrrole-2-
carboxamido]pyrazole-5-carboxamido]pyrazole-5-
carboxamido]propionamidoxime;
FAB-MS: m/z 741, (100, [M+H]⁺)
PMR (DMSO-d₆) δ :
10 11.10 (s, 1H), 10.51 (s, 1H), 10.01 (s, 1H), 8.83 (t, J=5.7Hz, 1H), 8.79 (t, J=5.7Hz, 1H), 7.53 (s, 1H), 7.43 (m, 2H), 7.40 (d, J=1.8 Hz, 1H), 7.38 (d, J=15.6Hz), 7.29 (s, 1H), 7.28 (s, 1H), 7.01 (d, J=1.8 Hz, 1H), 6.79 (m, 2H), 6.55 (d, J=15.6Hz), 4.03 (s, 3H), 4.01 (s, 3H), 3.86 (s, 3H), 3.75 (m, 8H), 3.52 (m, 2H), 2.70 (t, J=6.3Hz, 1H), 2.58 (t, J=6.3Hz, 2H);
3-[1-methyl-3[1-methyl-4[1-methyl-4[4-N,N-bis(2-
chloroethyl)aminocinnamoylamido]pyrrole-2-
carboxamido]pyrrole-2-carboxamido]pyrazole-5-
15 carboxamido]propioncyanamide;
3-[1-methyl-4[1-methyl-3[1-methyl-4[4-N,N-bis(2-
chloroethyl)aminocinnamoylamido]pyrrole-2-
carboxamido]pyrazole-5-carboxamido]imidazole-2-
carboxamido]propioncyanamide;
20 3-[1-methyl-4[1-methyl-4[1-methyl-4[4-N-ethyl-N(2-
chloroethyl)aminocinnamoylamido]pyrrole-2-
carboxamido]pyrrole-2-carboxamido]imidazole-2-
carboxamido]propioncyanamide;
3-[1-methyl-4[1-methyl-3[1-methyl-4[4-N,N-bis(2-
30 chloroethyl)aminocinnamoylamido]pyrrole-2-
carboxamido]pyrazole-5-carboxamido]imidazole-2-
carboxamido]propioncyanamide;
3-[1-methyl-3[1-methyl-4[1-methyl-4[4-N,N-bis(2-
chloroethyl)aminocinnamoylamido]pyrrole-2-
35 carboxamido]pyrrole-2-carboxamido]pyrazole-5-carboxamido]
propion-N,N'-dimethyl-amidine;
3-[1-methyl-4[1-methyl-4[1-methyl-4[4-N,N-bis(2-

chloroethyl)aminocinnamoylamido]pyrrole-2-
carboxamido]pyrrole-2-carboxamido]imidazole-2-carboxamido]
propion-N,N'-dimethyl-amidine;
3-[1-methyl-4[1-methyl-3[1-methyl-4[4-N,N-bis(2-
5 chloroethyl)aminocinnamoylamido]pyrrole-2-
carboxamido]pyrazole-5-carboxamido]imidazole-2-carboxamido]
propion-N,N'-dimethyl-amidine;
3-[1-methyl-4[1-methyl-3[1-methyl-4[4-N,N-bis(2-
chloroethyl)aminocinnamoylamido]pyrrole-2-
10 carboxamido]pyrazole-5-carboxamido]pyrrole-2-carboxamido]
propion-N,N'-dimethyl-amidine;
3-[1-methyl-3[1-methyl-3[1-methyl-4[4-N,N-bis(2-
chloroethyl)amino-3-methylcinnamoylamido]pyrrole-2-
carboxamido]pyrazole-5-carboxamido]pyrazole-5-carboxamido]
15 propion-N,N'-dimethyl-amidine;
3-[1-methyl-4[1-methyl-4[1-methyl-4[4-N-ethyl-N(2-
chloroethyl)aminocinnamoylamido]pyrrole-2-
carboxamido]pyrrole-2-carboxamido]imidazole-2-carboxamido]
propion-N,N'-dimethyl-amidine;
20 3-[1-methyl-4[1-methyl-3[1-methyl-4[4-N,N-bis(2-
chloroethyl)aminocinnamoylamido]pyrrole-2-
carboxamido]pyrazole-5-carboxamido]imidazole-2-
carboxamido]propionamide;
3-[1-methyl-3[1-methyl-3[1-methyl-4[4-N,N-bis(2-
25 chloroethyl)aminocinnamoylamido]pyrrole-2-
carboxamido]pyrazole-5-carboxamido]pyrazole-5-carboxamido]
propion-N-methyl-amidine;
3-[1-methyl-4[1-methyl-4[1-methyl-4[4-N,N-bis(2-
chloroethyl)aminocinnamoylamido]pyrrole-2-
30 carboxamido]pyrrole-2-carboxamido]imidazole-2-carboxamido]
propion-N-methyl-amidine;
3-[1-methyl-4[1-methyl-3[1-methyl-4[4-N,N-bis(2-
chloroethyl)aminocinnamoylamido]pyrrole-2-
carboxamido]pyrazole-5-carboxamido]imidazole-2-carboxamido]
35 propion-N-methyl-amidine;
3-[1-methyl-4[1-methyl-3[1-methyl-4[4-N,N-bis(2-
chloroethyl)aminocinnamoylamido]pyrrole-2-

carboxamido]pyrazole-5-carboxamido]imidazole-2-
carboxamido]propionitrile;

Example 3

5 3-[1-methyl-3[1-methyl-3[1-methyl-4[N,N-bis(2-
chloroethyl)aminocinnamoylamido]pyrrole-2-
carboxamido]pyrazole-5-carboxamido]pyrazole-5-
carboxamido]propionamidine

Step I The intermediate 1-methyl-4[N,N-bis(2-
10 chloroethyl)aminocinnamoylamido]pyrrole-2-carboxylic acid
A solution of 4-N,N'-bis(2-chloroethyl)amino-1-cinnamic
acid (100 mg) (prepared as reported in WO 97/43258),
dicyclohexylcarbodiimide (80 mg), 1-hydroxybenzotriazole
hydrate (50 mg) in DMF (8 ml) was stirred at 70°C for four
15 hours, cooled to room temperature and then added of 1-
methyl-4-aminopyrrole-2-carboxylic acid (70 mg) and
potassium bicarbonate (60 mg).

The mixture was stirred at room temperature for 3 hours,
the solvent was evaporated in vacuo and the crude residue
20 purified by flash chromatography (methylene
chloride/methanol: 9/1) to yield the intermediate compound
as a yellow powder (120 mg).

Step II The title compound

To a solution of 3[1-methyl-3[1-methyl-3-aminopyrazole-5-
25 carboxamido]pyrazole-5-carboxamido]propionamidine
dihydrochloride (prepared as reported in WO 96/05196) (200
mg), intermediate from step I (200 mg), N-(3-
dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride
(120 mg), triethylamine (0.15 ml) in DMF (10 ml) was
30 stirred at r.t. overnight. The solvent was evaporated in
vacuo and the crude residue purified by flash
chromatography (methylene chloride/methanol: 8/2) to yield
the title compound as an orange powder (250 mg).

FAB-MS: m/z 750, (30, [M+H]⁺); 772(100, [M+Na]⁺)
35 PMR (DMSO-d₆) d:
11.09 (s, 1H), 10.50 (s, 1H), 9.99 (s, 1H), 8.70 (b.s.,
2H), 8.20 (b.s., 1H), 7.52 (s, 1H), 7.43 (m, 2H), 7.40 (d,

J=1.8 Hz, 1H), 7.38 (d, J=15.6 Hz, 1H), 7.26 (s, 1H), 7.00 (d, J=1.8 Hz, 1H), 6.79 (m, 2H), 6.54 (d, J=15.6 Hz, 1H), 4.02 (s, 3H), 4.00 (s, 3H), 3.86 (s, 3H), 3.75 (m, 8H), 3.50 (b.s., 2H), 2.70 (b.s., 2H);

5 By analogous procedure and using the opportune starting materials the following products can be obtained:

3-[1-methyl-4[1-methyl-4[1-methyl-4[4-N,N-bis(2-chloroethyl)aminocinnamoylamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]imidazole-2-

10 carboxamido]propionamidoxime;

3-[1-methyl-4[1-methyl-3[1-methyl-4[4-N,N-bis(2-chloroethyl)aminocinnamoylamido]pyrrole-2-carboxamido]pyrazole-5-carboxamido]imidazole-2-carboxamido]propionamidoxime;

15 3-[1-methyl-4[1-methyl-3[1-methyl-4[4-N,N-bis(2-chloroethyl)aminocinnamoylamido]pyrrole-2-carboxamido]pyrazole-5-carboxamido]pyrrole-2-carboxamido]propionamidoxime;

3-[1-methyl-3[1-methyl-3[1-methyl-4[4-N-ethyl-N(2-

20 chloroethyl)aminocinnamoylamido]pyrrole-2-carboxamido]pyrazole-5-carboxamido]pyrazole-5-carboxamido]propionamidoxime;

3-[1-methyl-3[1-methyl-4[1-methyl-4[4-N,N-bis(2-

25 chloroethyl)amino-3-methylcinnamoylamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]pyrazole-5-carboxamido]propionamidoxime;

3-[1-methyl-3[1-methyl-3[1-methyl-4[4-N,N-bis(2-

30 chloroethyl)aminocinnamoylamido]pyrrole-2-carboxamido]pyrazole-5-carboxamido]pyrazole-5-carboxamido]propionitrile;

3-[1-methyl-4[1-methyl-3[1-methyl-4[4-N,N-bis(2-

chloroethyl)aminocinnamoylamido]pyrrole-2-

35 carboxamido]pyrazole-5-carboxamido]pyrrole-2-carboxamido]propionitrile;

3-[1-methyl-4[1-methyl-4[1-methyl-4[4-N,N-bis(2-

chloroethyl)aminocinnamoylamido]pyrrole-2-

carboxamido]pyrrole-2-carboxamido]imidazole-2-

carboxamido]propionamide;
 3-[1-methyl-3[1-methyl-4[1-methyl-4[4-N,N-bis(2-chloroethyl)aminocinnamoylamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]pyrazole-5-carboxamido]
 5 propion-N-methyl-amidine;
 3-[1-methyl-4[1-methyl-4[1-methyl-4[4-N,N-bis(2-chloroethyl)aminocinnamoylamido]pyrrole-2-carboxamido]pyrrole-2-imidazole-2-carboxamido]propion-N-methyl-amidine;
 10 2-[1-methyl-3[1-methyl-3[1-methyl-4[4-N,N-bis(2-chloroethyl)aminocinnamoylamido]pyrrole-2-carboxamido]pyrazole-5-carboxamido]pyrazole-5-carboxamido]ethylguanidine;
 15 2-[1-methyl-4[1-methyl-4[1-methyl-4[4-N,N-bis(2-chloroethyl)aminocinnamoylamido]pyrrole-2-carboxamido]pyrrole-2-imidazole-2-carboxamido]ethylguanidine;
 20 2-[1-methyl-3[1-methyl-3[1-methyl-4[3-N,N-bis(2-chloroethyl)aminocinnamoylamido]pyrrole-2-carboxamido]pyrazole-5-carboxamido]pyrazole-5-carboxamido]ethylguanidine.

Example 4

Tablets each weighing 0.250 g and containing 50 mg of the active substance can be manufactured as follows:

Composition for 10,000 tablets	
3-[1-methyl-3[1-methyl-4[1-methyl-4[4-N,N-bis(2-chloroethyl)aminocinnamoylamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]propionamidine hydrochloride	500 g
Lactose	1,400 g
Corn starch	500 g
Talc powder	80 g
Magnesium stearate	20 g

3-[1-methyl-4[1-methyl-4[1-methyl-4[4-N,N-bis(2-chloroethyl) aminocinnamoylamido]pyrrole-2-carboxamido]pyrrole-2-

carboxamido]propionamidine hydrochloride, lactose and half of the corn starch were mixed; the mixture was then forced through a sieve of 0.5 mm mesh size.

Corn starch (10 g) was suspended in warm water (90 ml) and
5 the resulting paste was used to granulate the powder. The granulate was dried, comminuted on a sieve of 1.4 mm mesh size, then the remaining quantity of starch, talc and magnesium stearate was added, carefully mixed and processed into tablets.

10

Example 5

Capsules, each dosed at 0.200 g and containing 20 mg of the active substance can be prepared as follows:

Composition for 500 capsules	
3-[1-methyl-3[1-methyl-4[4-N,N-bis(2-chloroethyl)aminocinnamoylamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]pyrazole-5-carboxamido]propionamidine hydrochloride	10 g
Lactose	80 g
Corn starch	5 g
Magnesium stearate	5 g


This formulation can be encapsulated in two-piece hard
15 gelatin capsules and dosed at 0.200 g for each capsule.

Example 6Intramuscular Injection 25 mg/ml

An injectable pharmaceutical composition can be
20 manufactured by dissolving 25 g of 3-[1-methyl-3[1-methyl-4[1-methyl-4[4-N,N-bis(2-chloroethyl)aminocinnamoylamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]pyrazole-5-carboxamido]propionamidine hydrochloride in sterile propyleneglycol
25 (1000 ml) and sealing ampoules of 1-5 ml.

CLAIMS

1. A compound which is a cinnamoyl distamycin derivative of formula:



5

wherein:

n is 2, 3 or 4;


R₀ is C₁-C₄ alkyl or C₁-C₃ haloalkyl;

R₁ and R₂, which are the same or different, are selected from hydrogen, C₁-C₄ alkyl optionally substituted by one or more fluorine atoms; and C₁-C₄ alkoxy;

X is a halogen atom;

Y and Z are the same or different and are selected independently for each heterocyclic ring of the polyheterocyclic chain, from N and CH;

B is selected from:



wherein R₃, R₄, R₅, R₆, and R₇ are, independently from each other, hydrogen or C₁-C₄ alkyl;

or pharmaceutically acceptable salts thereof;
provided that at least one of the heterocyclic rings within the polyheterocyclic chain is other than pyrrole.

2. A compound according to claim 1, wherein:

25 n is 3;


R_0 is ethyl or 2-chloroethyl;

R_1 and R_2 , which are the same or different, are selected from hydrogen, methyl, methoxy or trifluoromethyl;

X is chloro;

5 Y and Z are the same or different and are selected, independently for each heterocyclic ring of the polyheterocyclic chain, from N and CH;

B is selected from:



10

wherein R_3 , R_4 , R_5 , R_6 , and R_7 are, independently from each other, hydrogen or methyl;

or pharmaceutically acceptable salts thereof;

provided that at least one of the heterocyclic rings within 15 the polyheterocyclic chain is other than pyrrole..

3. A compound of formula (I) according to claim 1, selected from the group consisting of:

3-[1-methyl-3[1-methyl-3[1-methyl-4[4-N,N-bis(2-chloroethyl)aminocinnamoylamido]pyrrole-2-carboxamido]pyrazole-5-carboxamido]pyrazole-5-carboxamido]propionamidine;

3-[1-methyl-3[1-methyl-3[1-methyl-4[4-N-ethyl-N-(2-chloroethyl)aminocinnamoylamido]pyrrole-2-carboxamido]pyrazole-5-carboxamido]propionamidine;

3-[1-methyl-3[1-methyl-3[1-methyl-4[3-N,N-bis(2-chloroethyl)aminocinnamoylamido]pyrrole-2-carboxamido]pyrazole-5-carboxamido]pyrazole-5-carboxamido]propionamidine;

3-[1-methyl-3[1-methyl-3[1-methyl-4[3-methyl-4-N,N-bis(2-chloroethyl)aminocinnamoyl]pyrrole-2-carboxamido]pyrazole-5-carboxamido]pyrazole-5-carboxamido]propionamidine;

3-[1-methyl-3[1-methyl-4[1-methyl-4[4-N,N-bis(2-chloroethyl)aminocinnamoylamido]pyrrole-2-

carboxamido]pyrrole-2-carboxamido]pyrazole-5-
carboxamido]propionamidine;
3-[1-methyl-3[1-methyl-4[1-methyl-4[4-N-ethyl-N(2-
chloroethyl)aminocinnamoylamido]pyrrole-2-
5 carboxamido]pyrrole-2-carboxamido]pyrazole-5-
carboxamido]propionamidine;
3-[1-methyl-4[1-methyl-4[1-methyl-4[4-N,N-bis(2-
chloroethyl)aminocinnamoylamido]pyrrole-2-
carboxamido]pyrrole-2-carboxamido]imidazole-2-
10 carboxamido]propionamidine;
3-[1-methyl-4[1-methyl-3[1-methyl-4[4-N,N-bis(2-
chloroethyl)aminocinnamoylamido]pyrrole-2-
carboxamido]pyrazole-5-carboxamido]imidazole-2-
carboxamido]propionamidine;
15 3-[1-methyl-4[1-methyl-3[1-methyl-4[4-N,N-bis(2-
chloroethyl)aminocinnamoylamido]pyrrole-2-
carboxamido]pyrazole-5-carboxamido]pyrrole-2-
carboxamido]propionamidine;
3-[1-methyl-3[1-methyl-3[1-methyl-4[4-N,N-bis(2-
20 chloroethyl)aminocinnamoylamido]pyrrole-2-
carboxamido]pyrazole-5-carboxamido]pyrazole-5-
carboxamido]propioncyanamidine;
3-[1-methyl-3[1-methyl-4[1-methyl-4[4-N,N-bis(2-
chloroethyl)aminocinnamoylamido]pyrrole-2-
25 carboxamido]pyrrole-2-carboxamido]pyrazole-5-
carboxamido]propioncyanamidine;
3-[1-methyl-4[1-methyl-4[1-methyl-4[4-N,N-bis(2-
chloroethyl)aminocinnamoylamido]pyrrole-2-
carboxamido]pyrrole-2-carboxamido]imidazole-2-
30 carboxamido]propioncyanamidine;
3-[1-methyl-4[1-methyl-3[1-methyl-4[4-N,N-bis(2-
chloroethyl)aminocinnamoylamido]pyrrole-2-
carboxamido]pyrazole-5-carboxamido]imidazole-2-
carboxamido]propioncyanamidine;
35 3-[1-methyl-4[1-methyl-3[1-methyl-4[4-N,N-bis(2-
chloroethyl)aminocinnamoylamido]pyrrole-2-
carboxamido]pyrazole-5-carboxamido]pyrrole-2-

carboxamido]propioncyanamide;

3-[1-methyl-4[1-methyl-4[1-methyl-4[4-N-ethyl-N(2-chloroethyl)aminocinnamoylamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]imidazole-2-

5 carboxamido]propioncyanamide;

3-[1-methyl-4[1-methyl-3[1-methyl-4[4-N-ethylN(2-chloroethyl)aminocinnamoylamido]pyrrole-2-carboxamido]pyrazole-5-carboxamido]imidazole-2-carboxamido]propioncyanamide;

10 3-[1-methyl-3[1-methyl-3[1-methyl-4[4-N,N-bis(2-chloroethyl)aminocinnamoylamido]pyrrole-2-carboxamido]pyrazole-5-carboxamido]propionamidoxime;

3-[1-methyl-3[1-methyl-4[1-methyl-4[4-N,N-bis(2-

15 chloroethyl)aminocinnamoylamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]pyrazole-5-carboxamido]propionamidoxime;

3-[1-methyl-4[1-methyl-4[1-methyl-4[4-N,N-bis(2-chloroethyl)aminocinnamoylamido]pyrrole-2-

20 carboxamido]pyrrole-2-carboxamido]imidazole-2-carboxamido]propionamidoxime;

3-[1-methyl-4[1-methyl-3[1-methyl-4[4-N,N-bis(2-chloroethyl)aminocinnamoylamido]pyrrole-2-

25 carboxamido]pyrazole-5-carboxamido]imidazole-2-carboxamido]propionamidoxime;

3-[1-methyl-4[1-methyl-3[1-methyl-4[4-N,N-bis(2-chloroethyl)aminocinnamoylamido]pyrrole-2-

30 carboxamido]pyrazole-5-carboxamido]pyrrole-2-carboxamido]propionamidoxime;

3-[1-methyl-3[1-methyl-4[1-methyl-4[4-N-ethyl-N(2-chloroethyl)aminocinnamoylamido]pyrrole-2-

35 carboxamido]pyrrole-2-carboxamido]pyrazole-5-carboxamido]propionamidoxime;

3-[1-methyl-3[1-methyl-3[1-methyl-4[4-N,N-bis(2-chloroethyl)aminocinnamoylamido]pyrrole-2-carboxamido]pyrazole-5-carboxamido]pyrazole-5-carboxamido]propionitrile;

5 3-[1-methyl-3[1-methyl-4[1-methyl-4[4-N,N-bis(2-chloroethyl)aminocinnamoylamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]pyrazole-5-carboxamido]propionitrile;

10 3-[1-methyl-4[1-methyl-4[1-methyl-4[4-N,N-bis(2-chloroethyl)aminocinnamoylamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]imidazole-2-carboxamido]propionitrile;

15 3-[1-methyl-4[1-methyl-3[1-methyl-4[4-N,N-bis(2-chloroethyl)aminocinnamoylamido]pyrrole-2-carboxamido]pyrazole-5-carboxamido]imidazole-2-carboxamido]propionitrile;

20 3-[1-methyl-4[1-methyl-3[1-methyl-4[4-N,N-bis(2-chloroethyl)aminocinnamoylamido]pyrrole-2-carboxamido]pyrazole-5-carboxamido]pyrrole-2-carboxamido]propionitrile;

25 3-[1-methyl-3[1-methyl-3[1-methyl-4[4-N,N-bis(2-chloroethyl)aminocinnamoylamido]pyrrole-2-carboxamido]pyrazole-5-carboxamido]propionamide;

30 3-[1-methyl-4[1-methyl-4[1-methyl-4[4-N,N-bis(2-chloroethyl)aminocinnamoylamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]imidazole-2-carboxamido]propionamide;

35 3-[1-methyl-4[1-methyl-3[1-methyl-4[4-N,N-bis(2-chloroethyl)aminocinnamoylamido]pyrrole-2-carboxamido]pyrazole-5-carboxamido]imidazole-2-carboxamido]propionamide;


3-[1-methyl-3[1-methyl-3[1-methyl-4[4-N,N-bis(2-

chloroethyl)aminocinnamoylamido]pyrrole-2-
carboxamido]pyrazole-5-carboxamido]pyrazole-5-
carboxamido]propion-N-methyl-amidine;
3-[1-methyl-3[1-methyl-4[1-methyl-4[4-N,N-bis(2-
5 chloroethyl)aminocinnamoylamido]pyrrole-2-
carboxamido]pyrrole-2-carboxamido]pyrazole-5-
carboxamido]propion-N-methyl-amidine;
3-[1-methyl-4[1-methyl-4[1-methyl-4[4-N,N-bis(2-
chloroethyl)aminocinnamoylamido]pyrrole-2-
10 carboxamido]pyrrole-2-carboxamido]imidazole-2-
carboxamido]propion-N-methyl-amidine;
3-[1-methyl-4[1-methyl-3[1-methyl-4[4-N,N-bis(2-
chloroethyl)aminocinnamoylamido]pyrrole-2-
carboxamido]pyrazole-5-carboxamido]imidazole-2-
15 carboxamido]propion-N-methyl-amidine;
3-[1-methyl-3[1-methyl-3[1-methyl-4[4-N,N-bis(2-
chloroethyl)aminocinnamoylamido]pyrrole-2-
carboxamido]pyrazole-5-carboxamido]pyrazole-5-
carboxamido]propion-N,N'-dimethyl-amidine;
20 3-[1-methyl-3[1-methyl-4[1-methyl-4[4-N,N-bis(2-
chloroethyl)aminocinnamoylamido]pyrrole-2-
carboxamido]pyrrole-2-carboxamido]pyrazole-5-
carboxamido]propion-N,N'-dimethyl-amidine;
3-[1-methyl-4[1-methyl-4[1-methyl-4[4-N,N-bis(2-
25 chloroethyl)aminocinnamoylamido]pyrrole-2-
carboxamido]pyrrole-2-carboxamido]imidazole-2-
carboxamido]propion-N,N'-dimethyl-amidine;
3-[1-methyl-4[1-methyl-3[1-methyl-4[4-N,N-bis(2-
chloroethyl)aminocinnamoylamido]pyrrole-2-
30 carboxamido]pyrazole-5-carboxamido]imidazole-2-
carboxamido] propion-N,N'-dimethyl-amidine;
3-[1-methyl-4[1-methyl-3[1-methyl-4[4-N,N-bis(2-
chloroethyl)aminocinnamoylamido]pyrrole-2-
carboxamido]pyrazole-5-carboxamido]pyrrole-2-
35 carboxamido]propion-N,N'-dimethyl-amidine;
3-[1-methyl-3[1-methyl-3[1-methyl-4[3-methyl-4-N,N-bis(2-
chloroethyl)aminocinnamoylamido]pyrrole-2-


carboxamido]pyrazole-5-carboxamido]pyrazole-5-carboxamido]
propion-N,N'-dimethyl-amidine;
3-[1-methyl-4[1-methyl-4[1-methyl-4[4-N-ethyl-N(2-
chloroethyl)aminocinnamoylamido]pyrrole-2-
5 carboxamido]pyrrole-2-carboxamido]imidazole-2-
carboxamido]propion-N,N'-dimethyl-amidine;
2-[1-methyl-3[1-methyl-3[1-methyl-4[4-N,N-bis(2-
chloroethyl)aminocinnamoylamido]pyrrole-2-
carboxamido]pyrazole-5-carboxamido]pyrazole-5-
10 carboxamido]ethylguanidine;
2-[1-methyl-3[1-methyl-4[1-methyl-4[4-N,N-bis(2-
chloroethyl)aminocinnamoylamido]pyrrole-2-
carboxamido]pyrrole-2-carboxamido]pyrazole-5-
carboxamido]ethylguanidine;
15 2-[1-methyl-4[1-methyl-4[1-methyl-4[4-N,N-bis(2-
chloroethyl)aminocinnamoylamido]pyrrole-2-
carboxamido]pyrrole-2-carboxamido]imidazole-2-
carboxamido]ethylguanidine;
2-[1-methyl-3[1-methyl-3[1-methyl-4[3-N,N-bis(2-
20 chloroethyl)aminocinnamoylamido]pyrrole-2-
carboxamido]pyrazole-5-carboxamido]pyrazole-5-
carboxamido]ethylguanidine; and the pharmaceutically
acceptable salts thereof.

25 4. A process for preparing a compound as claimed in
claim 1, which process comprises:


- (a) when B is other than guanidino;
reacting a compound of formula:



30 with a compound of formula:




wherein n, X, R₀, R₁, R₂, Y and Z are as defined in claim 1; and E is hydroxy or a suitable leaving group; so as to obtain a compound of formula:



5


and then, optionally reacting a compound of formula (Ia) with:

(i) H₂N-(CH₂)_r-NH₂, wherein r is 2 or 3, so as to obtain a compound of formula (I) having B equal to:




10

(ii) H₂N-CN, so obtaining a compound of formula (I) having B equal to:




15


(iii) H₂N-OH, so obtaining a compound of formula (I) having B equal to:




(iv) HNR₄R₅, so obtaining a compound of formula (I) having B equal to:



and then optionally with H_2NR_3 , so obtaining a compound of formula (I) having B equal to:




- (v) succinic anhydride, so obtaining a compound of formula (I) having B equal to $-C\equiv N$;
- 5 (vi) water in an alkaline medium, so obtaining a compound of formula (I) having B equal to $-CONR_6R_7$, wherein R_6 and R_7 are both hydrogen atoms;
- (vii) HNR_6R_7 , so obtaining a compound of formula (I) having B equal to:




and then with water in an alkaline medium, so obtaining a compound of formula (I) having B equal to $-CONR_6R_7$, wherein R_6 and R_7 are, each independently, hydrogen or C_1-C_4 alkyl; or:

- 15 (b) reacting a compound of formula:



with a compound of formula:



20 wherein n, B, Y, Z, X, R_0 , R_1 , R_2 and E are as defined above; so obtaining the corresponding compound of formula (I); and, if desired, converting the compound of formula (I) prepared according to processes (a) or (b) into a

pharmaceutically acceptable salt thereof.

5. A process according to claim 4 wherein, within the compounds of formula (III), E is a leaving group selected from the group consisting of chloro, 2,4,5-trichlorophenoxy, 2,4-dinitro-phenoxy, succinimido-N-oxy and imidazolyl group.

10 6. A compound as defined in any one of claims 1 to 3 for use in a method of treating the human or animal body by therapy.

15 7. A compound as claimed in claim 6 for use as an antineoplastic agent.

8. Use of a compound as defined in any one of claims 1 to 3 in the manufacture of a medicament for use in the treatment of cancer.

20 9. A pharmaceutical composition which comprises an effective amount of a compound as defined in any one of claims 1 to 3 as an active principle, in association with one or more pharmaceutically acceptable carriers and/or diluents.

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/EP 99/03595

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C07D403/14 A61K31/415

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07D A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 97 43258 A (PHARMACIA AND UPJOHN S.P.A., ITALY; COZZI, PAOLO; BERIA, ITALO; CALDARE) 20 November 1997 (1997-11-20) cited in the application abstract; claims page 24 -page 29; example 1 ---	1,6-9
Y	WO 96 05196 A (PHARMACIA SPA ;BERIA ITALO (IT); PESENTI ENRICO (IT); CAPOLOGNO LA) 22 February 1996 (1996-02-22) cited in the application abstract; claims page 36 -page 40; example 1 ---	1,6-9 -/--

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

1 November 1999

Date of mailing of the international search report

12/11/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patenttaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl.
Fax: (+31-70) 340-3016

Authorized officer

Paisdor, B

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 99/03595

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	COZZI, PAOLO ET AL: "Novel phenyl nitrogen mustard and half-mustard derivatives of distamycin A" BIOORG. MED. CHEM. LETT. (1997), 7(23), 2985-2990 , XP004136570 abstract page 2986; examples 1,2 page 2989, paragraph 2 -----	1,6-9
Y	COZZI, PAOLO ET AL: "Novel phenyl nitrogen mustard and half-mustard derivatives of amidino-modified distamycin" BIOORG. MED. CHEM. LETT. (1997), 7(23), 2979-2984 , XP004136569 abstract page 2980; examples 1,2 page 2983, paragraph 3 -----	1,6-9

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 99/03595

Patent document cited in search report	Publication date	Patent family member(s)			Publication date
WO 9743258	A 20-11-1997	AU 2701697 A			05-12-1997
		EP 0912509 A			06-05-1999
		NO 985307 A			12-01-1999
		PL 329878 A			12-04-1999
WO 9605196	A 22-02-1996	AU 689623 B			02-04-1998
		AU 3113695 A			07-03-1996
		CA 2172629 A			22-02-1996
		CN 1131946 A			25-09-1996
		EP 0722446 A			24-07-1996
		FI 961506 A			05-06-1996
		HU 76267 A			28-07-1997
		JP 9504039 T			22-04-1997
		NO 961377 A			30-05-1996
		NZ 290404 A			24-04-1997
		PL 313821 A			22-07-1996
		US 5753629 A			19-05-1998
		ZA 9506590 A			18-03-1996

THIS PAGE BLANK (USPTO)